Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Gemcitabine chemoradiation plus panitumumab for locally advanced pancreatic cancer
NL-OMON36705Phase 2Active, not recruiting
- Sponsor
- Vrije University Medical Center
- Start
- Jul 2010
- Modality
- Small Molecules, Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 2, open-label trial of panitumumab and gemcitabine in pancreatic cancer (PC) (2 arms), sponsored by Vrije University Medical Center. Primary endpoints: Recommended safe dose of panitumumab in combination chemoradiation, Alive and progression-free at 7 months and 1 more. Started Jul 2010; status: active, not recruiting.
02
Drugs
panitumumabgemcitabine
03
Conditions
pancreatic cancer (PC)
Beyond the preview
Go deeper on NL-OMON36705.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON36705.